Matches in Wikidata for { <http://www.wikidata.org/entity/Q91555943> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q91555943 description "artículu científicu espublizáu en febreru de 2019" @default.
- Q91555943 description "scientific article published on 13 February 2019" @default.
- Q91555943 description "wetenschappelijk artikel" @default.
- Q91555943 description "наукова стаття, опублікована 13 лютого 2019" @default.
- Q91555943 name "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease" @default.
- Q91555943 name "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease" @default.
- Q91555943 type Item @default.
- Q91555943 label "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease" @default.
- Q91555943 label "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease" @default.
- Q91555943 prefLabel "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease" @default.
- Q91555943 prefLabel "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease" @default.
- Q91555943 P1433 Q91555943-8F0A8227-E546-4662-98CC-203AD59FAE8E @default.
- Q91555943 P1476 Q91555943-4C48C19E-E1C8-4099-90FC-69F0D51C1EB5 @default.
- Q91555943 P2093 Q91555943-477F5793-C65E-4660-B7EA-C383E82B7CAB @default.
- Q91555943 P2093 Q91555943-5F115074-AA77-4A91-90AF-BD6758D98443 @default.
- Q91555943 P2093 Q91555943-7ACA5C61-CE30-4AF5-88DC-44F382DFC6A6 @default.
- Q91555943 P2093 Q91555943-7F041877-8EF8-4CCE-84A0-13845F26803D @default.
- Q91555943 P2093 Q91555943-91CC23D5-8BBA-49D8-81A6-1F48C5CBAF9D @default.
- Q91555943 P2093 Q91555943-CD0C5F6B-8B3F-474B-B7F9-60943B158512 @default.
- Q91555943 P2093 Q91555943-E47AAB90-3819-4E9C-849F-7DC4B7DEB78B @default.
- Q91555943 P2093 Q91555943-F2F2FAC7-A9DB-4B23-BF3F-BD818D06F128 @default.
- Q91555943 P304 Q91555943-985AB39B-0C96-40B6-8953-42D60B1FAE93 @default.
- Q91555943 P31 Q91555943-54E521AC-0285-44AC-A3CF-DBBD79CF1CCD @default.
- Q91555943 P356 Q91555943-1E73C988-C5EC-4750-866C-1EB7F7A8032F @default.
- Q91555943 P433 Q91555943-315C83A4-97C2-438A-9803-3C8B4561DCE3 @default.
- Q91555943 P478 Q91555943-1B1BE16C-54CF-4F21-958F-82B58FD34249 @default.
- Q91555943 P50 Q91555943-BF5162B8-D249-43BF-9AAA-FC345F26A8D8 @default.
- Q91555943 P50 Q91555943-CD667645-F5AE-4366-A6F6-E9E7D1E4EBCE @default.
- Q91555943 P577 Q91555943-65AA09B0-E00F-4A64-BFC0-54AAB5A57738 @default.
- Q91555943 P698 Q91555943-903ECC69-E13D-40FE-9179-B9FF26446CDD @default.
- Q91555943 P921 Q91555943-508D9BAF-EE9D-4715-9E22-EA9FD22D6792 @default.
- Q91555943 P356 BLOOD-2018-11-884577 @default.
- Q91555943 P698 30760451 @default.
- Q91555943 P1433 Q885070 @default.
- Q91555943 P1476 "Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease" @default.
- Q91555943 P2093 "Ai-Lin Zhao" @default.
- Q91555943 P2093 "Dao-Bin Zhou" @default.
- Q91555943 P2093 "Ding-Rong Zhong" @default.
- Q91555943 P2093 "Jun Feng" @default.
- Q91555943 P2093 "Lu Zhang" @default.
- Q91555943 P2093 "Ming-Hui Duan" @default.
- Q91555943 P2093 "Xin-Xin Cao" @default.
- Q91555943 P2093 "Zhi-Yuan Li" @default.
- Q91555943 P304 "1720-1728" @default.
- Q91555943 P31 Q13442814 @default.
- Q91555943 P356 "10.1182/BLOOD-2018-11-884577" @default.
- Q91555943 P433 "16" @default.
- Q91555943 P478 "133" @default.
- Q91555943 P50 Q48357512 @default.
- Q91555943 P50 Q52983783 @default.
- Q91555943 P577 "2019-02-13T00:00:00Z" @default.
- Q91555943 P698 "30760451" @default.
- Q91555943 P921 Q50349818 @default.